Psyence Biomedical Ltd (PBM) Stock Price, Quote & News

Company Profile

Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.

Industry: Biotechnology

Sector: Healthcare

Phone: 416-477-1708

Website: psyencebiomed.com

Address:

121 Richmond Street West, Penthouse Suite 1300, Toronto, Canada

ExploringTrades Aug. 4 at 3:48 PM

Ticker NEXR has barely 550,000 shares outstanding. The only comparable ticker was VEEE and that one ran from 4.10$ to over 51$. NEXR released news on Aug 3rd and is shifting heavily into the AI sector. NEXR has only about 700 watchers on Stocktwits. Took a big position looking to profit massively very soon. $PBM All eyes

0 · Reply

TwinTurboBul161 Aug. 4 at 9:40 AM

$LASE $APVO $PBM On22

0 · Reply

Jbjb90 Jul. 30 at 11:57 PM

$PBM big volume compared to usual during both regular and after hours trading, lets get a phase 2 update or ibogane partnership news premarket tomorrow 🤞

0 · Reply

TwinTurboBul161 Jul. 30 at 10:55 PM

$PBM $SMWB •()watchlist

0 · Reply

Jockne40 Jul. 30 at 6:37 PM

$PBM broke out above 30 and 50 day moving averages on 4x normal volume today

0 · Reply

Jockne40 Jul. 30 at 6:23 PM

$PBM 298,000

0 · Reply

Jockne40 Jul. 30 at 6:21 PM

$PBM now 282,000

0 · Reply

Jockne40 Jul. 30 at 6:18 PM

$PBM average volume is 105,000

0 · Reply

Jockne40 Jul. 30 at 6:17 PM

$PBM 249,000. Something is brewing

0 · Reply

Jockne40 Jul. 30 at 6:16 PM

$PBM 235,000 now

0 · Reply

Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform

2026-05-15T14:51:49.000Z - 2 months ago

Psyence Biomedical announces U.S. engagement initiative focused on ibogaine

May 15, 2026, 9:15 AM EDT - 2 months ago

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

Apr 23, 2026, 7:00 AM EDT - 3 months ago

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

2026-04-20T12:19:33.000Z - 3 months ago

Psyence Biomedical provides update on position in global ibogaine market

Apr 20, 2026, 7:42 AM EDT - 3 months ago

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

2026-04-18T00:33:00.000Z - 3 months ago

Why Is Psyence Biomedical Stock (PBM) Up Today?

2026-04-17T19:16:22.000Z - 3 months ago

Psyence Biomedical Ltd trading resumes

2026-04-17T19:12:01.000Z - 3 months ago

Psyence Biomedical Ltd trading halted, volatility trading pause

2026-04-17T13:26:00.000Z - 3 months ago

Psyence acknowledges reports on U.S. action to advance Ibogaine research

Apr 17, 2026, 9:15 AM EDT - 3 months ago

Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine

Apr 8, 2026, 9:15 AM EDT - 4 months ago

Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities

Mar 11, 2026, 9:15 AM EDT - 5 months ago

Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

2026-03-03T14:22:48.000Z - 5 months ago

Psyence Biomedical announces export of psilocybin to Australia

Mar 3, 2026, 9:15 AM EST - 5 months ago

Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial

Feb 20, 2026, 5:20 PM EST - 5 months ago

Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment

2026-02-17T14:27:42.000Z - 6 months ago

Psyence Biomedical announces results of annual, special meeting

Feb 17, 2026, 9:15 AM EST - 6 months ago

Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

Feb 13, 2026, 6:30 PM EST - 6 months ago

Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway

2026-02-11T14:20:57.000Z - 6 months ago

Psyence Biomedical announces settlement of shareholder litigation

Feb 11, 2026, 9:15 AM EST - 6 months ago

Psyence BioMed Announces Settlement of Shareholder Litigation

Jan 28, 2026, 6:30 PM EST - 6 months ago

Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split

Jan 22, 2026, 1:42 PM EST - 6 months ago

Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026

Jan 20, 2026, 7:19 AM EST - 7 months ago

Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date

Jan 12, 2026, 8:30 AM EST - 7 months ago

Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity

Jan 5, 2026, 9:15 AM EST - 7 months ago

Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash

Dec 19, 2025, 7:00 AM EST - 8 months ago

Psyence BioMed Announces Approval for Use of PsyLabs' Psilocybin Product in Phase IIb Clinical Trial

Dec 9, 2025, 7:00 AM EST - 8 months ago

Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science

Nov 25, 2025, 7:00 AM EST - 9 months ago

Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program

Nov 20, 2025, 7:00 AM EST - 9 months ago

Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets

Nov 12, 2025, 7:00 AM EST - 9 months ago

Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs

Nov 6, 2025, 7:00 AM EST - 9 months ago

Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care

Nov 3, 2025, 7:00 AM EST - 9 months ago

Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment

Aug 28, 2025, 8:00 AM EDT - 1 year ago

Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Jul 31, 2025, 7:30 AM EDT - 1 year ago

Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

Jun 25, 2025, 5:00 PM EDT - 1 year ago

PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares

Jun 18, 2025, 5:36 PM EDT - 1 year ago

PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares

Jun 18, 2025, 8:30 AM EDT - 1 year ago

Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements

May 27, 2025, 7:30 AM EDT - 1 year ago

Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial

May 1, 2025, 7:30 AM EDT - 1 year ago

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

Apr 17, 2025, 7:17 PM EDT - 1 year ago

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apr 17, 2025, 9:39 AM EDT - 1 year ago

Psyence Group Announces Share Consolidation

Apr 15, 2025, 8:30 AM EDT - 1 year ago

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

Mar 18, 2025, 8:30 AM EDT - 1 year ago

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

Mar 10, 2025, 11:18 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.

Feb 26, 2025, 8:00 AM EST - 1 year ago

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.

Dec 27, 2024, 4:05 PM EST - 1 year ago

Psyence Biomed Announces Closing of $2.0 Million Private Placement

Dec 23, 2024, 7:30 AM EST - 1 year ago

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Dec 17, 2024, 8:37 AM EST - 1 year ago

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Dec 17, 2024, 7:30 AM EST - 1 year ago

Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial

Dec 10, 2024, 7:30 AM EST - 1 year ago

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Dec 6, 2024, 11:06 AM EST - 1 year ago

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

Dec 3, 2024, 7:30 AM EST - 1 year ago

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

Nov 19, 2024, 4:05 PM EST - 1 year ago

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Nov 12, 2024, 4:30 PM EST - 1 year ago

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

Oct 31, 2024, 9:30 AM EDT - 1 year ago

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

ExploringTrades Aug. 4 at 3:48 PM

0 · Reply

TwinTurboBul161 Aug. 4 at 9:40 AM

$LASE $APVO $PBM On22

0 · Reply

Jbjb90 Jul. 30 at 11:57 PM

$PBM big volume compared to usual during both regular and after hours trading, lets get a phase 2 update or ibogane partnership news premarket tomorrow 🤞

0 · Reply

TwinTurboBul161 Jul. 30 at 10:55 PM

$PBM $SMWB •()watchlist

0 · Reply

Jockne40 Jul. 30 at 6:37 PM

$PBM broke out above 30 and 50 day moving averages on 4x normal volume today

0 · Reply

Jockne40 Jul. 30 at 6:23 PM

$PBM 298,000

0 · Reply

Jockne40 Jul. 30 at 6:21 PM

$PBM now 282,000

0 · Reply

Jockne40 Jul. 30 at 6:18 PM

$PBM average volume is 105,000

0 · Reply

Jockne40 Jul. 30 at 6:17 PM

$PBM 249,000. Something is brewing

0 · Reply

Jockne40 Jul. 30 at 6:16 PM

$PBM 235,000 now

0 · Reply

Jockne40 Jul. 30 at 6:15 PM

$PBM big buy went thru volume jumped from 165,000 to 215,000

0 · Reply

am5198 Jul. 30 at 6:02 PM

$PBM Ive added twice today. Want to add more, but the market makers are stopping aggressive buys. Will buy as many as I can around here.

0 · Reply

longjohntrader Jul. 30 at 5:51 PM

$PBM mkt cap 11 million....with a small news...easy X10/20....120 million mkt Is.a.joke....

0 · Reply

FibQuants Jul. 30 at 5:48 PM

$PBM is on watch today. Holding up with some relative strength, and if volume stays in, it can keep pushing. Key is whether it can defend the current base and build above near-term resistance.

0 · Reply

Jockne40 Jul. 30 at 5:09 PM

$PBM breaking out of consolidation

0 · Reply

Jockne40 Jul. 30 at 5:08 PM

$PBM news due from PBM With big pharma buying psych mushroom companies

0 · Reply

mcfaddenmn Jul. 30 at 3:56 PM

$PBM https://www.newsnationnow.com/us-news/military/psilocybin-helps-most-vets-with-ptsd-small-study-shows/

0 · Reply

STWCommenter Jul. 30 at 3:52 PM

$PBM Hope something is brewing here

0 · Reply

longjohntrader Jul. 30 at 3:34 PM

$PBM

0 · Reply

learntoflyhigh Jul. 30 at 4:55 AM

$PBM

0 · Reply

Mantraset3 Jul. 28 at 9:10 PM

$PBM and $PPBT to 🏃 run

0 · Reply

PandaTrade_ Jul. 28 at 7:53 PM

Seems like Volume is going in to APUS fast now! 🚀 APUS is breaking out with huge NEWS released! Only 400k shares remaining - People are just finding it. Don't be late to APUS, It's going parabolic. $LASE $APVO $PBM $RAYA low float

0 · Reply

Market Cap	7.27M
Revenue (ttm)	0.00
Net Income (ttm)	-6.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	27,499
Avg Vol	80,896
Day's Range	N/A - N/A
Shares Out	2.29M
Stochastic %K	42%
Beta	1.67
Analysts	Strong Buy
Price Target	N/A